Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

The addition of concurrent cisplatin chemotherapy to adjuvant radiation therapy (CRT), versus RT alone, couldn't move the ...

These ingenious compounds bring together the DNA-damaging power of cisplatin and the immune-activating strength of STING agonist MSA-2. Excitingly, these conjugates exhibit remarkable potential as ...

Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

Chinese scientists have developed a new treatment for nasopharyngeal carcinoma that helps patients live longer and have a ...

Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of ...

The reference arm of paciltaxel and cisplatin for the Monk et al. 3 trial was selected on the basis of results from a GOG randomized phase III study, which demonstrated an improvement in objective ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...

The second group received no neoadjuvant therapy prior to surgery, followed by either standard of care radiotherapy with cisplatin (100mg/m 2 IV Q3W for 3 cycles) as adjuvant therapy following ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

The NOTOXIS trial (ClinicalTrials.gov ID: NCT05628233) evaluates the efficacy of SENS-401 in preventing CIO in adult patients with neoplastic disease, four weeks after completion of cisplatin ...